Re-treatment versus extended treatment strategy of systemic bevacizumab in hereditary hemorrhagic telangiectasia: which is better?
Letter to the Editor
- 12 Downloads
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 4.Sadick H, Riedel F, Naim R, Goessler U, Hormann K, Hafner M et al (2005) Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 90(6):818–828PubMedGoogle Scholar
© Springer-Verlag GmbH Germany, part of Springer Nature 2018